Image

LEAF (Liver Tumor dEtection And classiFication AI)

LEAF (Liver Tumor dEtection And classiFication AI)

Recruiting
18-90 years
All
Phase N/A

Powered by AI

Overview

This study aims to assess the feasibility of leveraging non-contrast CT and artificial intelligence to detect liver cancer in consecutive real-world patients. To this end, we deploy LEAF in a prospective real-world clinical setting for real-time monitoring, with a particular focus on flagging cases with liver cancer that may be missed by routine clinical workflow.

Description

This prospective real-world trial will be conducted at FAHZU, a high-volume tertiary medical center in mainland China.

LEAF will be deployed within the hospital information system through the DAMO Intelligent Medical Imaging interface, allowing it to flag potential liver lesions in real time. Approximately 2500 consecutive patients undergoing non-contrast CT examinations will be enrolled starting in July 2026. All incoming non-contrast chest and abdominal CT scans will be simultaneously reviewed by radiologists in routine clinical workflow and processed by LEAF in real-time. Daily logs of LEAF-positive alerts will be maintained by the research team. A prespecified clinical action committee composed of hepatobiliary surgeons and abdominal radiologists will review the case to assess whether the AI finding warrants communication to the treating physician of these patients. For patients with suspected malignant liver tumors, the committee's consensus on the presence of suspicious lesions will be communicated to their attending physicians, who will then decide whether additional diagnostic assessment is indicated according to standard clinical practice. The standard radiology workflow will not be altered by the study, and LEAF will be evaluated as a risk-stratification and case-flagging tool rather than a replacement for radiologist interpretation.

Eligibility

Inclusion Criteria:

Age range 18 years and above;

Underwent non-contrast chest or abdominal CT examination with liver coverage;

Patients with an established diagnosis of cirrhosis;

Patients with an established diagnosis of extrahepatic cancer.

Exclusion criteria:

Patients who have been diagnosed with malignant liver tumor;

Patients who underwent liver transplantation;

Low quality image, severe artifacts and noise.

Study details
    Liver Malignancy

NCT06859840

Zhejiang University

18 July 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.